These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 37523890)

  • 21. Machine Learning Analysis of Blood microRNA Data in Major Depression: A Case-Control Study for Biomarker Discovery.
    Qi B; Fiori LM; Turecki G; Trakadis YJ
    Int J Neuropsychopharmacol; 2020 Nov; 23(8):505-510. PubMed ID: 32365192
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Predictors of 4-week antidepressant outcome in patients with first-episode major depressive disorder: An ROC curve analysis.
    Zhou Y; Zhang Z; Wang C; Lan X; Li W; Zhang M; Lao G; Wu K; Chen J; Li G; Ning Y
    J Affect Disord; 2022 May; 304():59-65. PubMed ID: 35172174
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Open-label treatment with desvenlafaxine in postmenopausal women with major depressive disorder not responding to acute treatment with desvenlafaxine or escitalopram.
    Soares CN; Thase ME; Clayton A; Guico-Pabia CJ; Focht K; Jiang Q; Kornstein SG; Ninan PT; Kane CP
    CNS Drugs; 2011 Mar; 25(3):227-38. PubMed ID: 21323394
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A randomized, double-blind, 6-week prospective pilot study on the efficacy and safety of dose escalation in non-remitters in comparison to those of the standard dose of escitalopram for major depressive disorder.
    Kim EY; Kim SH; Lee HJ; Lee NY; Kim HY; Park CHK; Ahn YM
    J Affect Disord; 2019 Dec; 259():91-97. PubMed ID: 31445345
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Shared and Unique Changes in Brain Connectivity Among Depressed Patients After Remission With Pharmacotherapy Versus Psychotherapy.
    Dunlop BW; Cha J; Choi KS; Rajendra JK; Nemeroff CB; Craighead WE; Mayberg HS
    Am J Psychiatry; 2023 Mar; 180(3):218-229. PubMed ID: 36651624
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Anhedonia among patients with Major Depressive Disorder: A comparison between patients on escitalopram and healthy controls.
    Ng CG; Wong SK; Loh HS; Yee A
    Clin Ter; 2014; 165(6):e384-90. PubMed ID: 25524191
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of Functional and Structural Neural Network Features in Older Adults With Depression With vs Without Apathy and Association With Response to Escitalopram: Secondary Analysis of a Nonrandomized Clinical Trial.
    Oberlin LE; Victoria LW; Ilieva I; Dunlop K; Hoptman MJ; Avari J; Alexopoulos GS; Gunning FM
    JAMA Netw Open; 2022 Jul; 5(7):e2224142. PubMed ID: 35895056
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pre-treatment factor structures of the Montgomery and Åsberg Depression Rating scale as predictors of response to escitalopram in Indian patients with non-psychotic major depressive disorder.
    Basu A; Chadda R; Sood M; Rizwan SA
    Asian J Psychiatr; 2017 Aug; 28():154-159. PubMed ID: 28784374
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cognitive-functional relationships in major depressive disorder: Crucial data from a Ukrainian open-label study of vortioxetine versus escitalopram.
    Levada OA; Troyan AS
    J Affect Disord; 2019 May; 250():114-122. PubMed ID: 30852363
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Trajectories of individual symptoms in remitters versus non-remitters with depression.
    Sakurai H; Uchida H; Abe T; Nakajima S; Suzuki T; Pollock BG; Sato Y; Mimura M
    J Affect Disord; 2013 Nov; 151(2):506-513. PubMed ID: 23886402
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Improvement in subjective and objective neurocognitive functions in patients with major depressive disorder: a 12-week, multicenter, randomized trial of tianeptine versus escitalopram, the CAMPION study.
    Jeon HJ; Woo JM; Lee SH; Kim EJ; Chung S; Ha JH; Fava M; Mischoulon D; Kim JH; Heo JY; Yu BH
    J Clin Psychopharmacol; 2014 Apr; 34(2):218-25. PubMed ID: 24525660
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Whole-genome expression analysis reveals genes associated with treatment response to escitalopram in major depression.
    Pettai K; Milani L; Tammiste A; Võsa U; Kolde R; Eller T; Nutt D; Metspalu A; Maron E
    Eur Neuropsychopharmacol; 2016 Sep; 26(9):1475-1483. PubMed ID: 27461515
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Transcriptomic signatures of treatment response to the combination of escitalopram and memantine or placebo in late-life depression.
    Grzenda A; Siddarth P; Laird KT; Yeargin J; Lavretsky H
    Mol Psychiatry; 2021 Sep; 26(9):5171-5179. PubMed ID: 32382137
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Escitalopram maintenance treatment for prevention of recurrent depression: a randomized, placebo-controlled trial.
    Kornstein SG; Bose A; Li D; Saikali KG; Gandhi C
    J Clin Psychiatry; 2006 Nov; 67(11):1767-75. PubMed ID: 17196058
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Letter to the Editor: CONVERGENCES AND DIVERGENCES IN THE ICD-11 VS. DSM-5 CLASSIFICATION OF MOOD DISORDERS.
    Cerbo AD
    Turk Psikiyatri Derg; 2021; 32(4):293-295. PubMed ID: 34964106
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cognitive changes after tDCS and escitalopram treatment in major depressive disorder: Results from the placebo-controlled ELECT-TDCS trial.
    Moreno ML; Goerigk SA; Bertola L; Suemoto CK; Razza LB; Moffa AH; Veronezi BP; Tort L; Nogueira BS; Gattaz WF; Fraguas R; Padberg F; Lotufo PA; Benseñor IM; Brunoni AR
    J Affect Disord; 2020 Feb; 263():344-352. PubMed ID: 31969264
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Connectivity of the Cognitive Control Network During Response Inhibition as a Predictive and Response Biomarker in Major Depression: Evidence From a Randomized Clinical Trial.
    Tozzi L; Goldstein-Piekarski AN; Korgaonkar MS; Williams LM
    Biol Psychiatry; 2020 Mar; 87(5):462-472. PubMed ID: 31601424
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Escitalopram is more effective than citalopram for the treatment of severe major depressive disorder].
    Azorin JM; Llorca PM; Despiegel N; Verpillat P
    Encephale; 2004; 30(2):158-66. PubMed ID: 15107719
    [TBL] [Abstract][Full Text] [Related]  

  • 39. What to expect from a third step in treatment resistant depression: A prospective open study on escitalopram.
    Souery D; Calati R; Papageorgiou K; Juven-Wetzler A; Gailledreau J; Modavi D; Sentissi O; Pitchot W; Papadimitriou GN; Dikeos D; Montgomery S; Kasper S; Zohar J; Serretti A; Mendlewicz J
    World J Biol Psychiatry; 2015 Oct; 16(7):472-82. PubMed ID: 25535987
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combination antidepressant therapy for major depressive disorder: speed and probability of remission.
    Stewart JW; McGrath PJ; Blondeau C; Deliyannides DA; Hellerstein D; Norris S; Amat J; Pilowsky DJ; Tessier P; Laberge L; O'Shea D; Chen Y; Withers A; Bergeron R; Blier P
    J Psychiatr Res; 2014 May; 52():7-14. PubMed ID: 24485847
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.